Back to home » Treatment News
 March 31, 2008
|
Genes Predict Immune Response to Antiretroviral Treatment
A set of mutations to a person’s genes predicted how completely their immune system recovered after starting antiretroviral therapy, say the authors of a study to be published in a forthcoming issue of Nature Medicine and reported by Newswise.
|
|
|
March 27, 2008
|
Some People Not Appropriately Treated for High Cholesterol
Some HIV-positive people at high risk for heart disease are not having their levels of “bad” LDL cholesterol managed as aggressively as treatment guidelines recommend, say the authors of a single-clinic study published in the April 15 issue of Clinical Infectious Diseases.
|
|
|
March 26, 2008
|
Lower-Dose Zerit May Improve Some Side Effects
Halving the dose of Zerit (stavudine) may reduce the risk of serious side effects without compromising its efficacy, say researchers of a study published in the April 15 issue of Clinical Infectious Diseases.
|
|
|
March 25, 2008
|
Charting the Future of Protease Monotherapy
It has been suggested that using a Norvir (ritonavir)-boosted protease inhibitor (PI) without the use of other antiretrovirals to treat HIV is less effective, and more likely to cause drug resistance, than standard three-drug regimens in clinical trials.
|
|
|
March 24, 2008
|
Group Psychotherapy Improves Mood, but Not Adherence
A 12-week course of specialized psychological group counseling improved mood and quality of life in people living with HIV, but did not improve CD4 count, viral load or adherence to antiretroviral therapy, according to a study published in the March 30 issue of AIDS.
|
|
|
March 21, 2008
|
PIs Increase Heart Disease Risk, and NNRTIs Decrease It
Protease inhibitors (PIs) are associated with increased blood levels of fibrinogen—a marker of heart disease risk—whereas non-nucleoside reverse transcriptase inhibitors (NNRTIs) are associated with decreased blood levels of fibrinogen, according to a study published in the March 30 issue of AIDS.
|
|
|
March 20, 2008
|
Tenofovir Better Tolerated Than Zidovudine for PEP
Nonoccupational post-exposure prophylaxis (NPEP) regimens containing tenofovir were better tolerated and more likely to be completed than those containing zidovudine, according to a study conducted at the Fenway Community Health center in Boston and reported in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
March 19, 2008
|
Some Genetically Protected Against Lipoatrophy
Some people have genetic mutations that protect them from lipoatrophy, the loss of fat beneath the skin in the face and limbs caused by some HIV drugs, while others have genes that make them more vulnerable, say the authors of a new study published in the Journal of Infectious Diseases and reported by AIDSmap.
|
|
|
March 18, 2008
|
Mental Illness and Substance Use Delay HIV Treatment
People with untreated mental illness or substance abuse, or both together, start HIV treatment later than people without mental illness or substance abuse, according to a study published in the March 1 issue of AIDS Patient Care and STDs.
|
|
|
March 17, 2008
|
Universal Health Care Doesn’t Ensure Universal HIV Treatment
Forty percent of all those who died of AIDS in British Columbia, a province in Canada with true universal access to HIV care and treatment, died without having accessed HIV treatment, according to a study published in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
March 14, 2008
|
Trust for Doctors High in French Study
Though the vast majority of people living with HIV surveyed in France had a high degree of trust in their HIV doctor, a small percentage began to lose trust over time, say the authors of a new study.
|
|
|
March 13, 2008
|
Prezista Warning: Liver Problems Possible
Tibotec has updated its prescribing information for the protease inhibitor Prezista to include a warning about possible liver toxicity, according to a letter being sent to health care providers by the company in cooperation with the FDA.
|
|
|
Race and Gender Impact HIV Treatment Side Effects
Race and gender play a role in what side effects a person is likely to experience when starting an antiretroviral drug regimen, according to a study published in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
March 12, 2008
|
Mentally Ill and Substance Users Not Getting Care
A significant percentage of people living with HIV who have a diagnosed mental illness or a substance abuse problem, or both, are not getting appropriate treatment, according to a study published in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
March 11, 2008
|
Fish Oil and Fenofibrate an Effective Combo for High Triglycerides
The combination of fish oil with fenofibrate was more effective than either treatment alone in reducing triglycerides to desired levels in people living with HIV, according to a study published in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
March 10, 2008
|
Test for Abacavir Hypersensitivity Works in Black and White Patients
The HLA-B*5701 test to predict who will have a hypersensitivity reaction (HSR) to abacavir (found in Ziagen, Epzicom and Trizivir) works equally well in black and white patients with HIV, according to a study published in the April 1 issue of Clinical Infectious Diseases.
|
|
|
March 07, 2008
|
Genetically Reprogrammed Cells Could Battle HIV
Genetically reprogramming infection-fighting cells known as CD8 cytotoxic T lymphocytes (CTLs) made them especially efficient at wiping out HIV in laboratory experiments, report researchers at the Albert Einstein College in the Bronx.
|
|
|
March 06, 2008
|
Neuropathy Pain Patch Fails Test
A dermal patch that releases the experimental drug NGX-4010 for HIV-related distal sensory polyneuropathy (DSP), a painful condition caused by nerve damage, failed to perform better than a placebo in a phase III trial, according to NeurogesX, the developer of the compound.
|
|
|
Bevirimat Success Hinges on HIV Mutations
The experimental maturation inhibitor, Bevirimat (PA-457), is most effective in people whose virus does not carry a specific group of genetic mutations in HIV’s Gag protein, announced the drug’s developer, Panacos.
|
|
|
| March 05, 2008
|
March 04, 2008
|
Pneumonia Vaccine Effective in HIV
People with HIV who are given the pneumococcal polysaccharide vaccine (PPV) are 35 percent less likely to develop pneumonia than those who are not vaccinated, according to a new study to be published in an upcoming issue of Clinical Infectious Diseases.
|
|
|
March 03, 2008
|
Disalcid Improves Inflammation, But Has Liver Toxicity
The anti-inflammatory drug Disalcid (salsalate) reduces blood vessel inflammation, which may decrease the risk of a heart attack in people living with HIV, according to study results published in the March 12 issue of AIDS.
|
|
|
|
|
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com. |
|
  November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
|
